Compare OTIS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTIS | INSM |
|---|---|---|
| Founded | 1853 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | OTIS | INSM |
|---|---|---|
| Price | $90.45 | $169.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 22 |
| Target Price | $103.50 | ★ $187.30 |
| AVG Volume (30 Days) | 2.6M | ★ 3.7M |
| Earning Date | 01-28-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.39 | N/A |
| Revenue | ★ $14,310,000,000.00 | $447,022,000.00 |
| Revenue This Year | $3.74 | $43.95 |
| Revenue Next Year | $4.94 | $130.35 |
| P/E Ratio | $26.10 | ★ N/A |
| Revenue Growth | 0.73 | ★ 30.34 |
| 52 Week Low | $84.25 | $60.40 |
| 52 Week High | $106.83 | $212.75 |
| Indicator | OTIS | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 60.24 | 34.98 |
| Support Level | $88.30 | $167.39 |
| Resistance Level | $90.76 | $178.75 |
| Average True Range (ATR) | 1.36 | 5.52 |
| MACD | 0.31 | -0.81 |
| Stochastic Oscillator | 92.61 | 46.52 |
Otis is the largest global elevator and escalator supplier by revenue with around 18% global market share. In 1854 Otis' founder and namesake Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed. The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15- to 20-year useful life of an elevator. As the largest global OEM, Otis has amassed an installed base under service that exceeds 2 million elevators. Its business model is similar to that of its closest competitors Kone, Schindler, and TK Elevator.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.